BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 25200803)

  • 21. Cost-effectiveness of intensive atorvastatin treatment in high-risk patients compared with usual care in a postgeneric statin market: economic analysis of the Aggressive Lipid-lowering Initiation Abates New Cardiac Events (ALLIANCE) study.
    Mullins CD; Rattinger GB; Kuznik A; Koren MJ
    Clin Ther; 2008; 30 Pt 2():2204-16. PubMed ID: 19281915
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Resource use and cost implications of switching among warfarin formulations in atrial fibrillation patients.
    Kwong WJ; Kamat S; Fang C
    Ann Pharmacother; 2012 Dec; 46(12):1609-16. PubMed ID: 23150608
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of generic-only drug benefits on seniors' medication use and financial burden.
    Tseng CW; Brook RH; Keeler E; Steers WN; Waitzfelder BE; Mangione CM
    Am J Manag Care; 2006 Sep; 12(9):525-32. PubMed ID: 16961441
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis.
    Kesselheim AS; Misono AS; Lee JL; Stedman MR; Brookhart MA; Choudhry NK; Shrank WH
    JAMA; 2008 Dec; 300(21):2514-26. PubMed ID: 19050195
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Influence of substitution of brand name for generic drugs on therapeutic compliance in hypertension and dyslipidemia].
    Mainar AS; Artieda RN
    Gac Sanit; 2010; 24(6):473-82. PubMed ID: 20970220
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Are brand-name and generic warfarin interchangeable? A survey of Ontario patients and physicians.
    Pereira JA; Holbrook AM; Dolovich L; Goldsmith C; Thabane L; Douketis JD; Crowther M; Bates SM; Ginsberg JS
    Can J Clin Pharmacol; 2005; 12(3):e229-39. PubMed ID: 16278495
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A large observational study of cardiovascular outcomes associated with atorvastatin or simvastatin therapy in hypertensive patients without prior cardiovascular disease.
    Foody JM; Joyce AT; Jeffers BW; Liu LZ; Benner JS
    Am J Ther; 2011; 18(2):110-6. PubMed ID: 20216383
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
    Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
    Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Efficacy, safety, and pharmaco-economical aspects of the therapy for dyslipidemia with brand-name and generic statins].
    Ol'binskaia LI; Danilogorskaia IuA
    Ter Arkh; 2003; 75(12):47-50. PubMed ID: 14959470
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Brand name or generic? What are the health professionals prescribed for treating diabetes? A longitudinal analysis of the National Health Insurance reimbursement database.
    Liou WS; Hsieh SC; Chang WY; Wu GH; Huang HS; Lee C
    Pharmacoepidemiol Drug Saf; 2013 Jul; 22(7):752-9. PubMed ID: 23625864
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adherence to statin treatment and health outcomes in an Italian cohort of newly treated patients: results from an administrative database analysis.
    Degli Esposti L; Saragoni S; Batacchi P; Benemei S; Geppetti P; Sturani A; Buda S; Degli Esposti E
    Clin Ther; 2012 Jan; 34(1):190-9. PubMed ID: 22284998
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of generic cardiovascular medications by elderly Medicare beneficiaries receiving generalist or cardiologist care.
    Federman AD; Halm EA; Siu AL
    Med Care; 2007 Feb; 45(2):109-15. PubMed ID: 17224772
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Consequences on economic outcomes of generic versus brand-name drugs used in routine clinical practice: the case of treating peripheral neuropathic pain or generalized anxiety disorder with pregabalin.
    Sicras-Mainar A; Rejas-Gutiérrez J; Pérez-Paramo M; Sánchez-Alvarez L; Navarro-Artieda R; Darbà J
    Expert Rev Pharmacoecon Outcomes Res; 2019 Feb; 19(1):45-57. PubMed ID: 30182806
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In Medicare Part D plans, low or zero copays and other features to encourage the use of generic statins work, could save billions.
    Hoadley JF; Merrell K; Hargrave E; Summer L
    Health Aff (Millwood); 2012 Oct; 31(10):2266-75. PubMed ID: 23048108
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cholesterol level goal attainment with statins: clinical management guideline recommendations versus management in actual clinical practice.
    Heintjes EM; Penning-van Beest FJ; Plat AW; Meerding WJ; Webb K; Sturkenboom MC; Herings RM
    Pharmacotherapy; 2012 Jul; 32(7):631-41. PubMed ID: 22760692
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Therapeutic dose assessment of patient switching from atorvastatin to simvastatin.
    Hess G; Sanders KN; Hill J; Liu LZ
    Am J Manag Care; 2007 Jun; 13 Suppl 3():S80-5. PubMed ID: 17596116
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Therapeutic practice patterns related to statin potency and ezetimibe/simvastatin combination therapies in lowering LDL-C in patients with high-risk cardiovascular disease.
    Toth PP; Foody JM; Tomassini JE; Sajjan SG; Ramey DR; Neff DR; Tershakovec AM; Hu XH; Tunceli K
    J Clin Lipidol; 2014; 8(1):107-16. PubMed ID: 24528691
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative effectiveness of generic versus brand-name antiepileptic medications.
    Gagne JJ; Kesselheim AS; Choudhry NK; Polinski JM; Hutchins D; Matlin OS; Brennan TA; Avorn J; Shrank WH
    Epilepsy Behav; 2015 Nov; 52(Pt A):14-8. PubMed ID: 26386779
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Using default options within the electronic health record to increase the prescribing of generic-equivalent medications: a quasi-experimental study.
    Patel MS; Day S; Small DS; Howell JT; Lautenbach GL; Nierman EH; Volpp KG
    Ann Intern Med; 2014 Nov; 161(10 Suppl):S44-52. PubMed ID: 25402402
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Loss of response after switching from brand name to generic formulations: three cases and a discussion of key clinical considerations when switching.
    Margolese HC; Wolf Y; Desmarais JE; Beauclair L
    Int Clin Psychopharmacol; 2010 May; 25(3):180-2. PubMed ID: 20216221
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.